No Data
No Data
Jafron Biomedical (300529.SZ): The pHA series perfusion device has been widely used in more than 60 clinical hospitals, with a promising future application space.
On September 13, Gelunhui reported that jafron biomedical (300529.SZ) held a performance briefing on September 12, 2024 to discuss the clinical application and future prospects of the pHA series perfusion device. The company stated that the jafron pHA series blood perfusion device is the world's first product that can efficiently adsorb and remove medium-sized toxins and protein-bound toxins from the body of uremic patients, effectively reducing the risk of cardiovascular disease and protecting the heart and kidney health of patients. The pHA series perfusion device was officially launched and sold in November 2023, and has been promoted and used in more than 60 clinical hospitals, with a broad future application space.
Jafron Biomedical (300529.SZ): As of now, the company's products have been widely used in more than 2,000 hospitals overseas.
On September 12, 2024, Jafron Biomedical(300529.SZ) held a performance briefing to discuss the internationalization of the company's products. As of now, the company's products have been widely used in over 2,000 hospitals overseas, achieving market access in more than 90 countries. This year, the company's HA series blood perfusion equipment, BS series bilirubin adsorber, KHA series blood perfusion equipment, and CA series cytokine adsorption columns have successively obtained CE certification under the new EU MDR regulations, which will promote the company's products in EU countries and other EU MDR recognized countries.
Jafron Biomedical (300529.SZ): Subsidiary Zhuhai Jianshu Biomedical Materials project is expected to be put into operation before the end of 2024.
Jafron Biomedical (300529.SZ) stated on the investor interaction platform on September 12th that its subsidiary Zhuhai Jianshu Biomedical Materials project is currently under construction as planned and is expected to be put into operation by the end of 2024.
Jafron Biomedical (300529.SZ): CA and KHA products have obtained EU MDR certification.
Gelonghui September 3rd, jafron biomedical (300529.SZ) announced that the company has recently received a notification from the European Union announcing institutions that the company's product, Cell Affinity Column (CA) and Disposable Blood Perfusion Device (KHA), have been certified by the European Medical Devices Regulation (MDR) EU 2017/745, and can be sold in EU countries and other countries recognized by EU CE certification.
Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?
Jafron Biomedical (300529.SZ): Its new product, blood dialysis concentrate, from Hubei Jafron has obtained the third-class medical instrument registration certificate.
Jafron Biomedical (300529.SZ) announced on August 19th that its wholly-owned subsidiary, Hubei Jafron Biomedical Technology Co., Ltd. (hereafter referred to as "Hubei Jafron"), recently received the "Medical Instruments Registration Certificate" issued by the National Medical Products Administration for its new product, hemodialysis concentrate. The new product raises the limit indicators for microorganisms and endotoxins to be consistent with the standards for ultrapure dialysis fluid, representing an important layout for the company in the field of blood purification treatment.
No Data
No Data